New toxicity subscale measures QOL in cancer patients on checkpoint inhibitorsJanuary 11, 2020Cellular Therapy
CAR T cells produce complete responses in T-cell malignanciesJanuary 7, 2020ALLT Cell LymphomasCellular Therapy
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patientsDecember 23, 2019Multiple MyelomaCellular Therapy
‘Real-world’ data show CAR T therapies are cost effectiveDecember 13, 2019Business of MedicineCellular Therapy
An off-the-shelf drug to rival CAR T cells: ‘very exciting’December 13, 2019B Cell LymphomaCellular Therapy
Off-the-shelf cellular therapy shows promise in the labDecember 8, 2019B Cell LymphomaCLLCellular Therapy
Bispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Multiple MyelomaCellular Therapy
High complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Multiple MyelomaCellular Therapy
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTENovember 26, 2019Cellular TherapyALLMultiple Myeloma
Will TP53-mutated AML respond to immunotherapy?November 18, 2019AMLCellular TherapyTranslational Research
CAR T-cell ‘cocktail’ may overcome antigen escape relapseNovember 18, 2019B Cell LymphomaALLCellular Therapy
Armored CAR T cells elicit responses in NHL patientsNovember 12, 2019B Cell LymphomaDLBCLCellular Therapy
